<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antihypertensive medications for urgent blood pressure control in pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antihypertensive medications for urgent blood pressure control in pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antihypertensive medications for urgent blood pressure control in pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Drug</td> <td class="subtitle1">Initial dose</td> <td class="subtitle1">Follow-up</td> </tr> <tr class="divider_bottom"> <td rowspan="2">Labetalol</td> <td>20 mg IV gradually over 2 minutes.</td> <td>Repeat BP measurement at 10-minute intervals: <ul class="decimal_heading"> <li>If BP remains above target level at 10 minutes, give 40 mg IV over 2 minutes.</li> <li>If BP remains above target level at 20 minutes, give 80 mg IV over 2 minutes.</li> <li>If BP remains above target level at 30 minutes, give 80 mg IV over 2 minutes.</li> <li>If BP remains above target level at 40 minutes, give 80 mg IV over 2 minutes.</li> </ul> <p class="extra_spacing_top">Cumulative maximum dose is 300 mg. If target BP is not achieved, switch to another class of agent. Hold dose if heart rate &lt;60 beats per minute.</p> </td> </tr> <tr class="divider_bottom"> <td> <p>A continuous IV infusion of 1 to 2 mg/minute can be used instead of intermittent therapy or started after 20 mg IV dose.</p> Requires use of programmable infusion pump and continuous noninvasive monitoring of blood pressure and heart rate (reduce/discontinue infusion if heart rate &lt;60 beats per minute).</td> <td> <p>Adjust dose within this range to achieve target blood pressure.</p> Cumulative maximum dose is 300 mg. If target BP is not achieved, switch to another class of agent.</td> </tr> <tr class="divider_bottom"> <td>Hydralazine</td> <td> <p>5 mg IV gradually over 1 to 2 minutes.*</p> Adequate reduction of blood pressure is less predictable than with IV labetalol.</td> <td>Repeat BP measurement at 20-minute intervals: <ul class="decimal_heading"> <li>If BP remains above target level at 20 minutes, give 5 or 10 mg IV over 2 minutes, depending on the initial response.</li> <li>If BP remains above target level at 40 minutes, give 5 to 10 mg IV over 2 minutes, depending on the previous response.</li> </ul> <p class="extra_spacing_top">Cumulative maximum dose is 20 to 30 mg per treatment event. If target BP is not achieved, switch to another class of agent.</p> </td> </tr> <tr class="divider_bottom"> <td>Nicardipine (parenteral)</td> <td> <p>The initial dose is 5 mg/hour IV by continuous infusion titrated up to 15 mg/hour to achieve target BP 130 to 150/80 to 100 mmHg. The effect of dose titrations may not be observed for 5 to 15 minutes; rapid titration should be avoided to minimize risk of overshooting dose.</p> Requires use of a programmable infusion pump and continuous noninvasive monitoring of blood pressure and heart rate.</td> <td>Adjust dose within this range to achieve target BP.</td> </tr> <tr class="divider_bottom"> <td>Nifedipine immediate release*</td> <td>10 mg orally.</td> <td>Repeat BP measurement at 20-minute intervals: <ul class="decimal_heading"> <li>If BP remains above target at 20 minutes, give 10 or 20 mg orally, depending on the initial response.</li> <li>If BP remains above target at 40 minutes, give 10 or 20 mg orally, depending on the previous response.</li> </ul> <p class="extra_spacing_top">If target BP is not achieved, switch to another class of agent.</p> </td> </tr> <tr> <td>Nifedipine extended release</td> <td>30 mg orally.</td> <td> <p>If target BP is not achieved in 1 to 2 hours, another dose can be administered.</p> If target BP is not achieved, switch to another class of agent.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IV: intravenous; BP: blood pressure; FHR: fetal heart rate.</p>
* We caution against use of immediate-release oral nifedipine, although some obstetric guidelines have endorsed its use as a first-line option for emergency treatment of acute, severe hypertension in pregnancy or postpartum (other options were labetalol and hydralazine), particularly when IV access is not in place. In most cases, use of immediate-release oral nifedipine will be safe and well tolerated; however, there is a risk of an acute, precipitous fall in blood pressure, which may result in a reduction in uteroplacental perfusion. The immediate-release preparations are also associated with a higher incidence of headache and tachycardia. In nonpregnant adults, the package insert states that "nifedipine capsules should not be used for the acute reduction of blood pressure."</div><div class="graphic_reference">Adapted from:
<ol>
<li>American College of Obstetricians and Gynecologists. Gestational hyertension and preeclampsia. Practice Bulletin, Number 222. Obstet Gynecol 2020; 135:e237.</li>
<li>Bernstein PS, Martin JN Jr, Barton JR, et al. National Partnership for Maternal Safety: Consensus Bundle on Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol 2017; 130:347.</li>
</ol></div><div id="graphicVersion">Graphic 110261 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
